View Abstract
Harvey Bumpers
Predictive Molecular Markers of Colorectal Cancer for African-American Patients
Abstract Text:
Predictive Molecular Markers of Colorectal Cancer for African-American Patients Harvey Bumpers, M.D., F.A.C.S.,1 and Upender Manne, M.S., Ph.D. 2 1Department of Surgery, Morehouse School of Medicine, Atlanta, GA, and 2Department of Pathology, University of Alabama at Birmingham, Birmingham, AL. Presenter: Harvey Bumpers, M.D., Morehouse School of Medicine, 720 Westview Dr., S.W., Atlanta, GA, 30310. Office: 404-616-3562 email: hbumpers@msm.edu Target population: Medical and surgical oncologists, basic and translational science researchers Abstract: Colorectal cancer (CRC) is the second leading cause of cancer deaths. For 2011, 141,270 Americans are expected to be diagnosed with CRC, which is anticipated to cause 49,380 deaths. Patients with Stage II or III CRCs are considered for adjuvant 5-fluorouracil (5FU)-based chemotherapy. There is a persistent racial disparity in death rates for African Americans (AAs) with CRCs. Over the past four years, as part of our collaboration project on the U54 partnership (CA118948), we evaluated tissues samples of 912 sporadic CRCs (432 AAs and 480 non-Hispanic Caucasians) for selected phenotypic (p53, Bcl-2, and Bax) and genetic abnormalities (mutations in the p53 gene and microsatellite instability, MSI), and correlated the derived values with therapy response and patient survival. The results revealed that patients with low levels of Bax and Bcl-2 expression were benefitted most by chemotherapy. A single nucleotide polymorphism in the p53 gene was associated with aggressiveness of CRCs in AAs but not in Caucasian patients. MSI was a good prognostic indicator for both racial groups; however, low-MSI was associated with poor survival of Caucasian but not AA patients. Increased expressions of miR-21, miR-181b, and miR-203 in CRCs were strongly associated with poor survival of AA but not Caucasian patients. Our investigations have shown that the adult comorbidity evaluation-27 is an appropriate method for estimating comorbidity indices for a medical record-based dataset of CRCs. Overall, our findings suggest that race should be considered in designing therapy regimens and provide a basis for larger clinical trials.
Predictive Molecular Markers of Colorectal Cancer for African-American Patients
Abstract Text:
Predictive Molecular Markers of Colorectal Cancer for African-American Patients Harvey Bumpers, M.D., F.A.C.S.,1 and Upender Manne, M.S., Ph.D. 2 1Department of Surgery, Morehouse School of Medicine, Atlanta, GA, and 2Department of Pathology, University of Alabama at Birmingham, Birmingham, AL. Presenter: Harvey Bumpers, M.D., Morehouse School of Medicine, 720 Westview Dr., S.W., Atlanta, GA, 30310. Office: 404-616-3562 email: hbumpers@msm.edu Target population: Medical and surgical oncologists, basic and translational science researchers Abstract: Colorectal cancer (CRC) is the second leading cause of cancer deaths. For 2011, 141,270 Americans are expected to be diagnosed with CRC, which is anticipated to cause 49,380 deaths. Patients with Stage II or III CRCs are considered for adjuvant 5-fluorouracil (5FU)-based chemotherapy. There is a persistent racial disparity in death rates for African Americans (AAs) with CRCs. Over the past four years, as part of our collaboration project on the U54 partnership (CA118948), we evaluated tissues samples of 912 sporadic CRCs (432 AAs and 480 non-Hispanic Caucasians) for selected phenotypic (p53, Bcl-2, and Bax) and genetic abnormalities (mutations in the p53 gene and microsatellite instability, MSI), and correlated the derived values with therapy response and patient survival. The results revealed that patients with low levels of Bax and Bcl-2 expression were benefitted most by chemotherapy. A single nucleotide polymorphism in the p53 gene was associated with aggressiveness of CRCs in AAs but not in Caucasian patients. MSI was a good prognostic indicator for both racial groups; however, low-MSI was associated with poor survival of Caucasian but not AA patients. Increased expressions of miR-21, miR-181b, and miR-203 in CRCs were strongly associated with poor survival of AA but not Caucasian patients. Our investigations have shown that the adult comorbidity evaluation-27 is an appropriate method for estimating comorbidity indices for a medical record-based dataset of CRCs. Overall, our findings suggest that race should be considered in designing therapy regimens and provide a basis for larger clinical trials.
